The accumulated evidence was 17,031, 20,554, 4766, and 4646 times more likely to support the hypothesis that excellent response, NED in final follow-up, tumor size ≤10 mm, and classic cancer subtype, respectively, occur less frequently in patients with higher CHK2 expression. Here, CHEK2 is linked to cancer.